Oral Oncology
Volume 38, Issue 4 , Pages 349-356 , June 2002

Effect of herpes simplex virus type-1 on growth of oral cancer in an immunocompetent, orthotopic mouse model

  • E Lou

      Affiliations

    • Department of Microbiology and Immunology, SUNY Upstate Medical University, 750 East Adams Street, Syracuse NY 13210, USA
    • ,
  • R.M Kellman

      Affiliations

    • Department of Otolaryngology and Communication Sciences, SUNY Upstate Medical University, 750 East Adams Street, Syracuse NY 13210, USA
    • ,
  • E.J Shillitoe

      Affiliations

    • Department of Microbiology and Immunology, SUNY Upstate Medical University, 750 East Adams Street, Syracuse NY 13210, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-315-464-5453; fax: +1-315-464-4417

Received 11 June 2001 ,Accepted 18 June 2001.

References 

  1. Andreansky SS, He B, Gillespie GY, Soroceanu L, Markert J, Chou J, et al.  The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proceedings of the National Academy of Sciences (USA). 1996;93:11313–11318
  2. Coukos G, Makrigiannakis A, Kang EH, Caparelli D, Benjamin I, Kaiser LR, et al.  Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clinical Cancer Research. 1999;5:1523–1537
  3. Coukos G, Makrigiannakis A, Montas S, Kaiser LR, Toyozumi T, Benjamin I, et al.  Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy. Cancer Gene Therapy. 2000;7:275–283
  4. Randazzo BP, Kesari S, Gesser RM, Alsop D, Ford JC, Brown SM, et al.  Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant. Virology. 1995;211:94–101
  5. Randazzo BP, Bhat MG, Kesari S, Fraser NW, Brown SM. Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant. Journal of Investigative Dermatology. 1997;108:933–937
  6. Kucharczuk JC, Randazzo B, Chang MY, Amin KM, Elshami AA, Sterman DH, et al.  Use of a “replication-restricted” herpes virus to treat experimental human malignant mesothelioma. Cancer Research. 1997;57:466–471
  7. Shillitoe EJ, Gilchrist E, Pellenz C, Murrah V. Effects of herpes simplex virus on human oral cancer cells, and potential use of mutant viruses in therapy of oral cancer. Oral Oncology. 1999;35:326–332
  8. O'Malley BWJ, Cope KA, Johnson CS, Schwartz MR. A new immunocompetent murine model for oral cancer. Archives of Otolaryngology, Head and Neck Surgery. 1997;123:20–24
  9. Sales EW, Fitch KA, Sudetic PA, Schechter GL, Faulconer RJ, Somers KD. Growth and histopathology of human head and neck squamous cell carcinoma implanted intraorally in nude mice. Otolaryngology Head and Neck Surgery. 1991;104:357
  10. Simon C, Nemechek AJ, Boyd D, O'Malley BWJ, Goepfert H, Flaitz CM, et al.  An orthotopic floor-of-mouth cancer model allows quantification of tumor invasion. Laryngoscope. 1998;108:1686–1691
  11. Hier MP, Black MJ, Shenouda G, Sadeghi N, . Karp SE. A murine model for the immunotherapy of head and neck squamous cell carcinoma. Laryngoscope. 1995;105:1077–1080
  12. Schultz-Hector S, Haghayegh S. Beta-fibroblast growth factor expression in human and murine squamous cell carcinomas and its relationship to regional endothelial cell proliferation. Cancer Research. 1993;53:1444–1449
  13. O'Malley BW, Cope KA, Chen SH, Li D, Schwarta MR, Woo SL. Combination gene therapy for oral cancer in a murine model. Cancer Research. 1996;56:1737–1741
  14. Hong FD, Clayman GL. Isolation of a peptide for targeted drug delivery into human head and neck solid tumors. Cancer Research. 2000;60:6551–6556
  15. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Medicine. 1995;1:938–943
  16. Valyi-Nagy T, Fareed MU, O'Keefe JS, Gesser RM, MacLean AR, Brown SM, et al.  The herpes simplex virus type 1 strain 17+ gamma 34.5 deletion mutant 1716 is avirulent in SCID mice. Journal of General Virology. 1994;75:2059–2063
  17. Randazzo BP, Kucharczuk JC, Litzky LA, Kaiser LR, Brown SM, MacLean A, et al.  Herpes simplex 1716—an ICP 34.5 mutant—is severely replication restricted in human skin xenografts in vivo. Virology. 1996;223:392–395
  18. Bolovan CA, Sawtell NM, Thompson RL. ICP34.5 mutants of herpes simplex virus type 1 strain 17syn+ are attenuated for neurovirulence in mice and for replication in confluent primary mouse embryo cell cultures. Journal of Virology. 1994;68:48–55
  19. Perng GC, Ghiasi H, Slanina SM, Nesburn AB, Wechsler SL. High-dose ocular infection with a herpes simplex virus type 1 ICP34.5 deletion mutant produces no corneal disease or neurovirulence yet results in wild-type levels of spontaneous reactivation. Journal of Virology. 1996;70:2883–2893
  20. Glorioso JC, DeLuca NA, Fink DJ. Development and application of herpes simplex virus vectors for human gene therapy. Annual Review of Microbiology. 1995;49:675–710
  21. Alemany R, Balague C, Curiel DT. Replicative adenoviruses for cancer therapy. Nature Biotechnology. 2000;18:723–727
  22. Nemunaitis J, Khuri F, Ganly I, Arseneau J, Posner M, Vokes E, et al.  Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. Journal of Clinical Oncology. 2001;19:289–298
  23. Sadeghi N, Black MJ, Hier MP, Shenouda G, Karp SE. Generation of therapeutic T cells from draining lymph nodes in a murine model of head and neck squamous cell carcinoma. Archives of Otolaryngology, Head and Neck Surgery. 1997;123:25–30
  24. Dinesman A, Haughey B, Gates GA, Aufdemorte T, Von Hoff DD. Development of a new in vivo model for head and neck cancer. Otolaryngology Head and Neck Surgery. 1990;103:766–774
  25. O'Malley BWJ, Sewell DA, Li D, Kosai K, Chen SH, Woo SL, et al.  The role of interleukin-2 in combination with adenovirus gene therapy for head and neck cancer. Molecular Endocrinology. 1997;11:667–673
  26. Kirn D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the the treatment of cancer; what have we learned?. Gene Therapy. 2001;8:89–98
  27. Todo T, Rabkin SD, Martuza RL. Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors. Cancer Gene Therapy. 2000;7:939–946
  28. Ramesh R, Munshi A, Marrogi AJ, Freeman SM. Enhancement of tumor killing using a combination of tumor immunization and HSV-tk suicide gene therapy. International Journal of Cancer. 1999;80:380–386
  29. Bi W, Kim YG, Feliciano ES, Pavelic L, Wilson KM, Pavelic ZP, et al.  An HSVtk-mediated local and distant antitumor bystander effect in tumors of head and neck origin in athymic mice. Cancer Gene Therapy. 1997;4:246–252
  30. Heise CC, Williams A, Olesch J, Kirn DH. Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects. Cancer Gene Therapy. 1999;6:499–504
  31. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, et al.  A controlled trial of intratumoral ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nature Medicine. 2000;6:879–885
  32. Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T, et al.  Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus in patients with advanced head and neck cancer: a phase II trial. Cancer Research. 2000;60:6366
  33. Ikeda K, Ichikawa T, Wakimoto H, Silver JS, Deisboeck TS, Finkelstein D, et al.  Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nature Medicine. 1999;5:881–887
  34. Chahlavi A, Todo T, Martuza RL, Rabkin SD. Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia. 1999;1:162–169
  35. Wong RJ, Patel SG, Kim SH, DeMatteo RP, Malhotra S, Bennett JJ, et al.  Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Human Gene Therapy. 2001;12:253–265
  36. Lasner TM, Tal-Singer R, Kesari S, Lee VMY, Trojanowski JQ, Fraser NW. Toxicity and neuronal infection of a HSV-1 ICP34.5 mutant in nude mice. Journal of Neurovirology. 1998;3:100–105
  37. Carew JF, Kooby DA, Halterman MW, Federoff HJ, Fong Y. Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus Type-1 (G207). Human Gene Therapy. 1999;10:1599–1606

PII: S1368-8375(01)00069-0

Oral Oncology
Volume 38, Issue 4 , Pages 349-356 , June 2002

Article Tools

* Image Usage & Resolution